What is Vanda Pharmaceuticals?
Founded in 2003, Vanda Pharmaceuticals is a biopharmaceutical research and development entity committed to developing innovative therapies that enhance patient well-being. The company employs cutting-edge technologies, including genetics and genomics, to inform its drug discovery, clinical trial execution, and commercialization strategies. Vanda Pharmaceuticals focuses on creating novel therapeutic approaches and advanced delivery systems for its pharmaceutical products, maintaining a global footprint across North America, Europe, and Asia while pushing the boundaries of medical research for various health conditions.
How much funding has Vanda Pharmaceuticals raised?
Vanda Pharmaceuticals has raised a total of $57.5M across 2 funding rounds:
Stock Offering
$57.5M
Debt
$46K
Stock Issuance/Offering (2006): $57.5M, investors not publicly disclosed
Debt (2021): $46K led by PPP
Key Investors in Vanda Pharmaceuticals
PPP
Public-Private Partnership
What's next for Vanda Pharmaceuticals?
The recent influx of substantial expansion capital positions Vanda Pharmaceuticals for accelerated growth and strategic development. This financing is expected to fuel further research into novel therapeutic areas, potentially expand clinical trial capabilities, and bolster commercialization efforts for existing and pipeline products. The company's focus on leveraging advanced genetic and genomic insights suggests a strategic direction towards precision medicine and targeted therapies, aiming to solidify its market position and address unmet medical needs globally.
See full Vanda Pharmaceuticals company page
